Who
Julia A. Haller
Director
Company insider
Files Form 4 as: Director, Bristol-Myers Squibb; Director, Outlook Therapeutics; Director, Hyperion DeFi; Director, Celgene Corp /de/.
In numbers
- Trades disclosed
- 93
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 15 Jun 2016
- Last trade
- 15 Jun 2026
- Last filed
- 16 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 16 Jun 2026 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | $1.1M20,460 at $53.76 | filing |
| 15 Jun 2026filed 16 Jun 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —20,460 at $0.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —20,460 at $0.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | $1.1M20,460 at $53.76 | filing |
| 1 Feb 2026filed 3 Feb 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K3,996.367 at $55.05 | filing |
| 1 Feb 2026filed 3 Feb 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $220K3,996.37 at $55.05 | filing |
| 3 Oct 2025filed 3 Oct 2025 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —58,648 at $0.00 | filing |
| 1 Oct 2025filed 3 Oct 2025 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —286,734 at $0.00 | filing |
| 1 Feb 2025filed 4 Feb 2025 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $210K3,562.34 at $58.95 | filing |
| 3 Oct 2024filed 3 Oct 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,082 at $0.00 | filing |
| 1 Oct 2024filed 3 Oct 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,636 at $0.00 | filing |
| 1 Oct 2024filed 3 Oct 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,232 at $0.00 | filing |
| 7 Mar 2024filed 8 Mar 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —94,441 at $0.00 | filing |
| 1 Feb 2024filed 5 Feb 2024 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $210K4,314.77 at $48.67 | filing |
| 31 Dec 2023filed 3 Jan 2024 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $36K706.49 at $51.31 | filing |
| 4 Oct 2023filed 5 Oct 2023 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —210,225 at $0.00 | filing |
| 30 Sep 2023filed 3 Oct 2023 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $36K624.57 at $58.04 | filing |
| 30 Jun 2023filed 5 Jul 2023 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $35K553.94 at $63.95 | filing |
| 31 Mar 2023filed 4 Apr 2023 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $34K486.94 at $69.31 | filing |
| 29 Mar 2023filed 31 Mar 2023 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,065 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.